Waystar Holding (WAY) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Waystar Holding (WAY) right now is AI-driven revenue cycle automation: Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. Revenue (TTM) is ~$1.16B. If that keeps playing out, the setup is favourable; the risk to it is concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. No one can predict where WAY trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Waystar Holding (WAY) higher?
1. AI-driven revenue cycle automation
Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. Because medical billing is labor-intensive and error-prone, automation that lifts clean-claim rates and recovers denials is a concrete efficiency pitch to providers. This is the clearest lever the company points to for both new-logo wins and expansion within existing accounts.
2. Land-and-expand with high retention
Net revenue retention of about 111% means existing customers spend more each year as they adopt additional modules across the platform. With provider solutions growing organically at roughly double the pace of patient-payment solutions, cross-selling more of the suite into an already-large installed base is a durable growth engine. High switching costs in mission-critical billing systems reinforce the stickiness.
3. Iodine acquisition and platform breadth
The Iodine Software acquisition extended Waystar into mid-cycle and clinical-integrity capabilities, and management has said the integration is running ahead of schedule. Bolting complementary capabilities onto one platform lets Waystar sell a broader footprint to the same providers. Continued M&A and cross-sell of acquired capabilities are central to the growth story.
4. Structural demand for billing efficiency
US healthcare billing is famously complex, and providers face persistent margin pressure that makes faster, cleaner collections valuable. The addressable market for RCM software and transactions is often estimated in the $15-20 billion range annually. As a scaled independent platform, Waystar is positioned to consolidate share as providers move off fragmented legacy tools.
What could weigh on WAY?
Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a mid-30s P/E leaves little room for a growth or margin stumble, and the stock has traded well below its 52-week high. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history. Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
Where WAY trades today
A forecast starts from where the stock actually is. These are WAY's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for WAY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a WAY forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the WAY guide and whether WAY is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the WAY outlook
The bottom line: what is driving Waystar Holding (WAY) is AI-driven revenue cycle automation, with revenue (ttm) at ~$1.16B. If that keeps playing out the setup is favourable; the risk is concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. No one can predict the price, so treat any WAY forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around WAY with Walnut
Use Waystar Holding as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Waystar Holding (WAY)?
+
No one can reliably predict where WAY will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Waystar Holding higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive WAY higher?
+
The main growth drivers are AI-driven revenue cycle automation; Land-and-expand with high retention; Iodine acquisition and platform breadth. Whether they play out is the real question, not a guaranteed path.
What are the risks to WAY?
+
Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a mid-30s P/E leaves little room for a growth or margin stumble, and the stock has traded well below its 52-week high. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history. Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
Will WAY stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Waystar Holding's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is WAY a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the WAY "is it a buy?" page for a framework. Walnut is not an investment adviser.
How fast is Waystar growing?
+
Revenue grew about 22% year over year in Q1 2026 to roughly $314 million, of which about 11% was organic and the rest came from the Iodine Software acquisition. Full-year 2026 revenue guidance is roughly $1.274 billion to $1.294 billion.
Why did WAY stock trade below its highs in 2026?
+
Despite strong results, the stock traded well below its 52-week high in the first half of 2026, reflecting the market repricing a richly valued software name where investors weigh continued growth and margin gains against a high multiple and competitive pressure.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.